Scarica l'app Stockscreener
2.67
0.38%
0.010
Pre-mercato:
2.71
0.04
+1.50%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$2.66
Aprire:
$2.765
Volume 24 ore:
12.09M
Relative Volume:
1.56
Capitalizzazione di mercato:
$2.36B
Reddito:
$1.31M
Utile/perdita netta:
$-597.65M
Rapporto P/E:
-2.7526
EPS:
-0.97
Flusso di cassa netto:
$-425.62M
1 W Prestazione:
+5.53%
1M Prestazione:
+5.12%
6M Prestazione:
-46.28%
1 anno Prestazione:
-58.41%
Intervallo 1D:
$2.65
$2.88
Intervallo di 1 settimana:
$2.43
$2.88
Portata 52W:
$1.83
$7.63
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Confronta IBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.67 | 2.23B | 1.31M | -597.65M | -425.62M | -0.97 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva - Seeking Alpha
Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield? Platform, in Patients with Solid Tumors - marketscreener.com
FDA authorizes ANKTIVA for lymphopenia in cancer patients By Investing.com - Investing.com Canada
FDA authorizes ANKTIVA for lymphopenia in cancer patients - Investing.com Australia
Immunitybio Receives FDA Expanded Access Authorization For Landmark Treatment Of Lymphopenia With Anktiva - marketscreener.com
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors - Yahoo Finance
Deadline to Claim Your Payout from the $10.5M ImmunityBio Settlement Is in 1 Month - TradingView
Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, - openPR.com
Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma, ImmunityBio - The Globe and Mail
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
ImmunityBio: BioShield Platform Expands to Middle East and Other Important Updates - TradingView
ImmunityBio: Analyst Reaffirms $30 Price Target and Other Important Updates - TradingView
While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey
ImmunityBio (IBRX) Stock Rating and Price Target Update | IBRX S - GuruFocus
ImmunityBio (IBRX) Stock Rating and Price Target Update | IBRX Stock News - GuruFocus
Cancer BioShield Platform Comes to Saudi Arabia and the Middle East - Vax-Before-Travel
ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East - BioSpace
ImmunityBio Signs Agreement to Launch BioShield in Saudi Arabia, Middle East - marketscreener.com
Immunitybio, Inc. Signs Strategic Memorandum of Understanding to Launch Cancer Bioshield Platform in the Middle East - marketscreener.com
ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding - marketscreener.com
ImmunityBio (IBRX) Expands Cancer Treatment Platform to Middle E - GuruFocus
Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com
Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail
ImmunityBio Board Settles Shareholders’ Cancer Therapy Lawsuit - Bloomberg Law News
Why ImmunityBio, Inc. (IBRX) Crashed Today - MSN
Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT - Insider Monkey
Piper Sandler Upgrades ImmunityBio (NASDAQ:IBRX) to Overweight - Defense World
Jim Cramer Notes ImmunityBio (IBRX) Has “Been Losing Money Forever” - Insider Monkey
Piper Sandler Upgrades ImmunityBio (IBRX) - Nasdaq
10 Firms Drenched in Red Today - Insider Monkey
Jim Cramer’s Recent Thoughts on These 15 Stocks - Insider Monkey
Piper Sandler raises ImmunityBio stock rating, target to $5 By Investing.com - Investing.com Nigeria
ImmunityBio (IBRX) Upgraded to Overweight by Piper Sandler - GuruFocus
Why ImmunityBio, Inc. (IBRX) Surged Last Week - Insider Monkey
ImmunityBio upgraded to Overweight at Piper Sandler on Anktiva success - Seeking Alpha
ImmunityBio (IBRX) Receives Analyst Upgrade and Price Target Increase | IBRX Stock News - GuruFocus
Piper Sandler raises ImmunityBio stock rating, target to $5 - Investing.com
ImmunityBio (IBRX) Receives Upgrade with Promising Outlook on Ca - GuruFocus
ImmunityBio (IBRX) Receives Upgrade with Promising Outlook on Cancer Therapies | IBRX Stock News - GuruFocus
Why ImmunityBio’s Stock is on the Rise - TipRanks
ImmunityBio (IBRX) Receives Upgrade from Piper Sandler | IBRX Stock News - GuruFocus
Dimensional Fund Advisors LP Boosts Holdings in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal
Mercer Global Advisors Inc. ADV Purchases 8,359 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
ImmunityBio, Inc. (NASDAQ:IBRX) Holdings Decreased by Price T Rowe Associates Inc. MD - Defense World
Biotechs need a new guidebook to parse FDA messaging: a Perspective - BioCentury
Q2 Earnings Forecast for ImmunityBio Issued By HC Wainwright - Defense World
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00 - Yahoo
HC Wainwright Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX) - Defense World
Raymond James Financial Inc. Takes $172,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):